Company Description

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.

Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.

Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics, Inc.

Country	United States
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Junyi Dai

Contact Details

Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States
Phone	646 427 2727
Website	indaptusrx.com

Stock Details

Ticker Symbol	INDP
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1857044
CUSIP Number	45339J204
ISIN Number	US45339J2042
Employer ID	86-3158720
SIC Code	2834

Key Executives

Name	Position
Junyi Dai	Chief Executive Officer and Chairman
Yu Ding	Chief Financial Officer

Latest SEC Filings

Date	Type	Title
Sep 1, 2026	8-K	Current Report
Aug 31, 2026	424B5	Filing
Aug 26, 2026	424B3	Prospectus
Aug 25, 2026	EFFECT	Notice of Effectiveness
Aug 17, 2026	S-3	Registration statement under Securities Act of 1933
Aug 13, 2026	10-Q	Quarterly Report
Aug 13, 2026	8-K	Current Report
Jul 17, 2026	EFFECT	Notice of Effectiveness
Jul 16, 2026	DEF 14A	Other definitive proxy statements
Jun 26, 2026	SCHEDULE 13D/A	Filing

View All SEC Filings